Hudson Bay Capital Management’s Acceleron Pharma XLRN Stock Holding History

Hudson Bay Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,000	Closed	-$3.44M	–	1343
2021 Q3	$3.44M	Buy	+20,000	New	+$2.62M	0.05%	481
2020 Q3	–	Sell	-5,000	Closed	-$476K	–	670
2020 Q2	$476K	Buy	+5,000	New	+$482K	0.01%	413
2020 Q1	–	Sell	-150,000	Closed	-$7.95M	–	612
2019 Q4	$7.95M	Sell	150,000 -30,000	-17%	-$1.37M	0.18%	112
2019 Q3	$7.11M	Sell	180,000 -20,000	-10%	-$868K	0.2%	103
2019 Q2	$8.22M	Buy	200,000 +15,000	+8%	+$621K	0.19%	112
2019 Q1	$8.62M	Buy	185,000 +20,000	+12%	+$878K	0.11%	169
2018 Q4	$7.19M	Buy	165,000 +45,000	+38%	+$2.25M	0.1%	199
2018 Q3	$6.87M	Sell	120,000 -30,000	-20%	-$1.47M	0.08%	212
2018 Q2	$7.28M	Sell	150,000 -30,000	-17%	-$1.09M	0.1%	192
2018 Q1	$7.04M	Hold	180,000	–	–	0.15%	165
2017 Q4	$7.64M	Sell	180,000 -32,500	-15%	-$1.22M	0.16%	104
2017 Q3	$7.93M	Buy	212,500 +92,500	+77%	+$3.21M	0.2%	106
2017 Q2	$3.65M	Buy	120,000 +79,000	+193%	+$2.29M	0.07%	238
2017 Q1	$1.08M	Buy	+41,000	New	+$1.08M	0.01%	602

Hudson Bay Capital Management's XLRN Position: Q4 2021 in Review

Hudson Bay Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 20,000 shares — an estimated $3.44M sold.

Hudson Bay Capital Management first reported a position in XLRN in Q1 2017 and held it in 14 quarters. The position peaked at $8.62M in Q1 2019. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Hudson Bay Capital Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Hudson Bay Capital Management sold 20,000 Acceleron Pharma shares in Q4 2021, an estimated $3.44M.
Hudson Bay Capital Management first reported a position in Acceleron Pharma in Q1 2017 and held it in 14 quarters.
Hudson Bay Capital Management's Acceleron Pharma position peaked at $8.62M in Q1 2019.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Hudson Bay Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.